pGL3-VEGFR2-780 Citations (5)
Originally described in: A mechanosensitive transcriptional mechanism that controls angiogenesis.Mammoto A, Connor KM, Mammoto T, Yung CW, Huh D, Aderman CM, Mostoslavsky G, Smith LE, Ingber DE Nature. 2009 Feb 26. 457(7233):1103-8. PubMed Journal
Articles Citing pGL3-VEGFR2-780
| Articles |
|---|
| Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. Kumar BN, Rajput S, Dey KK, Parekh A, Das S, Mazumdar A, Mandal M. BMC Cancer. 2013 Jun 3;13:273. doi: 10.1186/1471-2407-13-273. PubMed |
| MicroRNA-199b Modulates Vascular Cell Fate During iPS Cell Differentiation by Targeting the Notch Ligand Jagged1 and Enhancing VEGF Signaling. Chen T, Margariti A, Kelaini S, Cochrane A, Guha ST, Hu Y, Stitt AW, Zhang L, Xu Q. Stem Cells. 2015 May;33(5):1405-18. doi: 10.1002/stem.1930. PubMed |
Thyroid Transcription Factor 1 Reprograms Angiogenic Activities of Secretome.
Wood LW, Cox NI, Phelps CA, Lai SC, Poddar A, Talbot C Jr, Mu D.
Sci Rep. 2016 Feb 25;6:19857. doi: 10.1038/srep19857.
PubMed
Associated Plasmids |
| Pseudopodium-enriched atypical kinase 1 mediates angiogenesis by modulating GATA2-dependent VEGFR2 transcription. Wang H, Lapek J, Fujimura K, Strnadel J, Liu B, Gonzalez DJ, Zhang W, Watson F, Yu V, Liu C, Melo CM, Miller YI, Elliott KC, Cheresh DA, Klemke RL. Cell Discov. 2018 May 29;4:26. doi: 10.1038/s41421-018-0024-3. eCollection 2018. PubMed |
| Newly developed preclinical models reveal broad-spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide. Matsuoka T, Sugiyama A, Miyawaki Y, Hidaka Y, Okuno Y, Sakai H, Tanaka H, Yoshikawa K, Fukui T, Mizuno K, Sumiyoshi T, Goto T, Inoue T, Akamatsu S, Kobayashi T, Nakamura E. Cancer Sci. 2024 Jan;115(1):283-297. doi: 10.1111/cas.15984. Epub 2023 Nov 3. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.